CFTR genotype and clinical outcomes of adult patients carried as cystic fibrosis disease
Introduction
Cystic fibrosis (CF) is a common autosomal recessive disorder within the Caucasian population with high lethality and morbidity (Farrel, 2000). It is caused by mutations in cystic fibrosis transmembrane conductance regulator (CFTR; ENSG00000001626) gene which encodes a chloride channel expressed on the surface of epithelial cells (Riordan et al., 1989). Nearly more than 2000 mutations have been described (http://www.genet.sickkids.on.ca/cftr) and divided into six categories depending on their effects on protein production and activity (Zielenski and Tsui, 1995, Haardt et al., 1999). I, II and III CFTR-class mutations are associated with a severe clinical status since there is no production of an active CFTR protein, while CFTR gene mutation Classes IV, V and VI are associated with a better prognosis since the channel has residual activity (Amaral and Kunzelmann, 2007). When CF disease was first described, patient's life was short and painful. However, antibiotics began to be widely used and pancreatic supplements became available, providing an aggressive treatment of symptoms, with higher life expectancy and quality of life improvement. In 2005, more than 35% of CF patients were over 18 years old (Davis, 2006) and it was expected that CF patients who were born in the 90s could live up to their 40s, while those who are born currently are expected to live 50 years of age (Cystic Fibrosis Foundation, 2008). Nowadays, as CF patients have bigger life expectancy, the adult population requiring medical care increased (Tuchman et al., 2010).
Around the world the transition process to adult life takes places at the end of adolescence or the first phase of adulthood. In these CF life phases, the pulmonary function should be decreasing, and both, load of treatment and multisystemic complications derived from the disease are increasing (Cystic Fibrosis Foundation, 2008, Dobbin and Bye, 2003, Konstan et al., 2009). Within this new perspective, studies that characterize this growing group are important.
Actually, with therapeutic advances in CF management and the competence of pediatricians, adults' physicians have to deal with two groups of patients: (i) adults diagnosed in childhood with severe mutations and (ii) adults who initiated symptoms in adulthood and with Class IV, V and VI mutations. In this context, the aim of this study was to analyze adults from a clinical center, carried as CF disease, screening the CFTR genotype, performing the sweat test and evaluating the clinical characteristics.
Section snippets
Patients and method
Cross-sectional study enrolled 30 patients carried as CF disease, older than 18 years old from State University of Campinas (Unicamp).
All patients showed clinical symptoms of CF, and received the treatment. All patients had done the sweat test and had a diagnosis of CF. The positive case of CF was considered as patients with two doses of sodium and chloride from the sweat with values greater than 60 mEq/L or two CFTR gene mutation identified by molecular technique.
Local Ethics Committees approved
Description of CF patients
From the patients carried as CF in the Center, five have normal sweat test and no CFTR mutation screened. For the clinical characterization and the associations, only patients with positive results screened in sweat test and/or CFTR mutation determined were enrolled. The complete patient's characteristics for sweat tests and CFTR genotype were described in Table 1. The clinical markers achieved in our data were shown in Table 2. The 25 CF patients had diagnosis performed in the first ages (mean =
Discussion
The study of typical CF disease is an important and knowledgeable area of medicine. Nowadays, CF can be considered as a disease for each patient, and a particular population needs to be analyzed: the adult CF patients. In our center, patients are treated in adults' clinical as CF patients, taking into account the clinical markers. To understand this particular sample, the present work performed the screening of CFTR mutations and analyzed the patient's records.
In our data, five patients had no
Conflict of interest
The authors declare that they have no competing interests.
Authors' contributions
LCB: made substantial contributions to conception and design, or acquisition of data, or analysis and interpretation of data; involved in drafting the manuscript or revising it critically for important intellectual content.
FALM: made substantial contributions to conception and design, or acquisition of data, or analysis and interpretation of data; involved in drafting the manuscript or revising it critically for important intellectual content.
JDR/IPA/MPC/AFR: has been involved in drafting the
Acknowledgments
Bruna Favetta — English review. Maria Angela Ribeiro — spirometry analysis. www.laboratoriomultiusuario.com.br by technical contribution. Anabela S. Ramalho to collaborate with CFTR mutation identification.
Financial support: Fapesp and CNPq.
References (22)
- et al.
Molecular targeting of CFTR as a therapeutic approach to cystic fibrosis
Trends in Pharmacological Sciences
(2007) - et al.
A novel donor splice site characterized by CFTR m RNA analysis induces a new pseudo-exon in CF patients
Journal of Cystic Fibrosis
(2010) - et al.
C-terminal truncations destabilize the cystic fibrosis transmembrane conductance regulator without impairing its biogenesis
Journal of Biological Chemistry
(1999) - et al.
Characterizing aggressiveness and predicting future progression of CF lung disease
Journal of Cystic Fibrosis
(2009) - et al.
Cystic fibrosis
Lancet
(2009) Pharmacogenomics in admixed populations
Trends in Pharmacological Sciences
(2005)- et al.
Cystic fibrosis: scoring system with thin-section CT
Radiology
(1991) - et al.
Variability of pulmonary function tests in cystic fibrosis
Pediatric Pulmonology
(1990) Cystic Fibrosis Foundation Annual Patient Registry Report
(2008)
Cystic fibrosis since 1938
American Journal of Respiratory and Critical Care Medicine
Cited by (37)
Equitable Expanded Carrier Screening Needs Indigenous Clinical and Population Genomic Data
2020, American Journal of Human GeneticsActivity of pulmonary vancomycin exposures versus planktonic and biofilm isolates of methicillin-resistant Staphylococcus aureus from cystic fibrosis sputum
2020, International Journal of Antimicrobial AgentsCitation Excerpt :Cystic fibrosis (CF) is an autosomal recessive genetic disorder associated with persistent lung infection [1,2].
Body Weight and Body Mass Index in Patients with End-Stage Cystic Fibrosis Stabilize After the Start of Enteral Tube Feeding
2017, Journal of the Academy of Nutrition and DieteticsCitation Excerpt :In our study sample, P aeruginosa colonization was observed in the majority of patients (85%). P aeruginosa can lead to increased energy demands35 and is associated with lung impairment.36,37 The low lung function in our patients may also be influenced by the high prevalence of P aeruginosa infection.
Variants in the interleukin 8 gene and the response to inhaled bronchodilators in cystic fibrosis
2017, Jornal de PediatriaCitation Excerpt :Mutations of the CFTR gene were analyzed by polymerase chain reaction (PCR; F508del) followed by enzymatic digestion (G542X, R1162X, R553X, G551D, and N1303K). Other mutations in the CFTR gene were identified by sequencing or with the use of the SALSA Multiplex Ligation-dependent Probe Amplification (MPLA method) Kit P091-C1 CFTR-MRC-Holland S4X, 2183A>G, 1717-G>A, I618T with MegaBace1000® (GE Healthcare Biosciences – Pittsburgh, USA), and ABI3500 (Applied Biosystems – Thermo Fisher Scientific – São Paulo, Brazil).17 IL-8 gene variants were analyzed by PCR followed by restriction enzyme digestion.
Association of clinical severity of cystic fibrosis with variants in the SLC gene family (SLC6A14, SLC26A9, SLC11A1 and SLC9A3)
2017, GeneCitation Excerpt :The CFTR mutations were analyzed by the techniques of polymerase chain reaction (PCR) for F508del and enzymatic digestion for G542X, R1162X, R553X, G551D and N1303K. Other mutations have been identified in CFTR by sequencing, or use of the technique of SALSA MLPA (Multiplex Ligation – dependent Probe Amplification) Kit P091-C1 CFTR-MRC-Holland: S4X, 2183A > G, 1717-G > A, I618T, with MegaBace1000® (GE Healthcare Biosciences, Pittsburgh, USA) and ABI 3500 (Applied Biosystems-Thermo Fisher Scientific, São Paulo/SP, Brazil) (Bonadia et al., 2014). Considering CFTR genotypes, patients were divided into three groups: (i) with two identified mutations belonging to class I, II and/or III; (ii) with an identified mutation belonging to class I, II and/or III; (iii) no mutation identified belonging to class I, II and/or III.